Category: <span>Biologics Production</span>

Large-Scale Production of Active Serine-Threonine Kinases of the MAPK Pathway Using the Baculovirus System

Serine-threonine kinases of the Mitogen Activated Protein Kinase (MAPK) pathway represent potential drug targets for a wide range of diseases. As part of an effort to understand the biology of the pathways, several human serine-threonine MAPKs were produced. Optimization and modification of current methodologies used in the baculovirus expression system resulted in the generation of large amounts of active MAPKs. Compounds found to inhibit the MAPKs in vitro, subsequently showed activity in cell-based assays and animal models. The processes to be discussed were developed to yield large quantities of three active human serine-threonine MAPKs by the baculovirus expression system…

Read MoreLarge-Scale Production of Active Serine-Threonine Kinases of the MAPK Pathway Using the Baculovirus System

Baculovirus Expression Technology Biologics Production

Production of a p55gag Particle Vaccine Using the Baculovirus Expression Vector System Technology

Globally, an estimated 36 million people are living with HIV, and some 20 million people have already died of AIDS. Today, there is still no HIV vaccine available. HIV virus-like particles are an attractive vaccine candidate due to their ability to induce both antibody and cytotoxic T-lymphocyte responses. In this article, we describe the development of a production process for an HIV particle vaccine, HIV-1 p55 (gag). The gag precursor protein (p55) is sufficient for assembly and cellular release of retrovirus-like particles. We expressed the p55 gag protein using the BEVS technology in Spodoptera frugiperda expresSF+ cells…

Read MoreProduction of a p55gag Particle Vaccine Using the Baculovirus Expression Vector System Technology

Baculovirus Expression Technology Biologics Production

HIV retrovirus-like particles vaccines virus-like particles

The Road Ahead for Biologics Manufacturing

Protein-based therapeutics have led to the emergence of the biotechnology industry and should drive rapid growth in the industry over the next decade. In 2001 alone, six major biologics were approved by the FDA. According to our analysis, there are 39 biologic products (antibodies and non-antibody recombinant proteins) that are currently in Phase III clinical testing and about 60 in Phase II testing, which we estimate could lead to 34 new products on the market in the next four to six years. By our estimates, such a new product outpouring would lead to more than a doubling of the number of profitable biopharmaceutical product companies (currently 15) by mid-decade. The focus of this report is to evaluate the manufacturing aspects of biotechnology models and analyze the current and future capacity needs of the industry…

Read MoreThe Road Ahead for Biologics Manufacturing

Biologics Production Manufacturing

biologics

Development of Capabilities for Small-Scale Virus Fills

Introgen Therapeutics has been producing clinical-grade adenoviral vectors in scaled-up processes, in cGMP facilities, for over five years. Semi-automated hand filling, using a Watson-Marlow 505Di/L pump, has been used over this period to fill batch sizes of up to 2 liters of adenovirus. While this procedure has been robust and demonstrated a high level of sterility assurance through regularly scheduled media fill studies and product testing, the firm needed to move to the next level of fill sizes. Anticipating up to 10,000 fills in 3 mL vials, Introgen has worked in collaboration with M&O Perry Corp. to develop an automated fill capability that utilizes the same base procedure but in an automated fashion…

Read MoreDevelopment of Capabilities for Small-Scale Virus Fills

Biologics Production Viral Vectors

adenoviral vectors adenovirus automation scale-up sterility

  1. Pages:
  3. 1
  4. ...
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32